Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

SEATTLE, Sept. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development. With these data and the previously announced encouraging results from the OMS824 positron emission tomography (PET) clinical trial, Omeros is advancing OMS824 into Phase 2 clinical programs. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.

The OMS824 Phase 1 clinical trial included single- and multiple-dose escalation studies that enrolled 100 healthy male subjects: 60 subjects received a single dose of OMS824, 24 subjects received multiple doses for seven to 10 days, and 16 subjects received placebo. The data announced today are at the highest multiple-dose level administered and, at this dose, OMS824 was well tolerated and the only apparent drug-related adverse events were mild. Almost all adverse events were self-limiting, resolving during the 10-day dosing period. In May of this year, Omeros reported that a lower dose evaluated in an ongoing PET clinical trial demonstrated target engagement greater than had previously been reported for any PDE10 inhibitor (an average of approximately 50-percent and a maximum of approximately 70-percent engagement) without the dose-limiting side effects seen with other PDE10 inhibitors. Pharmacokinetic data at the high dose announced today showed an approximately two-fold increase in plasma concentration over that of the dose used in the earlier-reported PET trial. This same high dose l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... REDWOOD CITY, Calif., July 19, 2011 Cardica, ... that Andreas Kuthe, M.D., Chief of General Surgery ... successfully completed a total of five laparoscopic procedures ... cutting and stapling device. These included several sigmoidectomies, ...
... Agility Health, a leading national provider ... patients, healthcare providers and employers, today announced the ... clinics.  Agility Health,s newest facility, located in Plainwell, ... to 23 owned or partnered facilities and follows ...
Cached Medicine Technology:Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 2Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 3Agility Health Expands National Outpatient Clinic Group with New Michigan Facility 2
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 Dr. ... with late stages of hair loss achieve great results in ... the Facial Hair Transplant , an FUE method that ... recipient area. This method lets patients whose hair loss ... head. Facial Hair Transplant is a great alternative for those ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
(Date:8/29/2014)... Astronauts may be at heightened risk of illness because ... new study suggests. That could be a real ... and Mars undertaken in the future, because getting a ... NASA researchers say. They found that the distribution ... Station crew members remains relatively unchanged during their time ...
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Healthpointe ... organizations, acquired a new medical center from LAXMed. The medical ... and less than 2 miles west of the 405 freeway. ... within Southern California. The new LAX center is located at: ... , The new Healthpointe LAX office will ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... types, study found , , SUNDAY, April 13 (HealthDay News) ... risk of breast cancer and particularly estrogen-receptor and progesterone-receptor ... findings, expected to be presented Sunday at the annual ... San Diego, are followed by a second study that ...
... (p. 46). Senior Editor David J. Jefferson writes,about the ... Ulysses S.,Grant High School, class of ,82 as part ... former classmates, Jefferson tells the,stories of those who lived ... the first for which divorce was just another part ...
... planning can stop allergy attacks in their tracks , , ... so is allergy season for millions of Americans. , ... many people can limit their suffering or perhaps even ... internal medicine and chief of allergy and clinical immunology at ...
... to Jeopardize Residents, Care, MILLBRAE, Calif., April ... will launch their second strike at,the facility in ... fairly over the workers, proposals to improve care., ... at 6 a.m. on Tuesday, April 15.,Caregivers launched ...
... They were least surprised when researchers got paid but ... 11 (HealthDay News) -- Many volunteers in clinical studies ... there is some loss of trust, suggests a U.S. ... a hypothetical clinical trial did not suffer substantially based ...
... have higher rates of depression than other Hispanics living ... by researchers at Hebrew SeniorLifes Institute for Aging Research ... make up 11 percent of the Hispanics 65 and ... to Mexican Americans, Cuban Americans, and Hispanics from Central ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Spring and Pollen Are in the Air 2Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2Health News:Researchers find disparities in depression among older Hispanics in US 2
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Medicine Products: